nach oben

Comparative Clinical Pathology

Erschienen in:

21.01.2017 | Original Article

Immunohistochemical expression of transforming growth factor Beta-1 in canine mammary carcinomas: its relationships with histologic grading, survival rate, and recurrence

verfasst von: Massoud Rezaee, Ahmad Reza Movassaghi, Mohsen Maleki

Erschienen in: Comparative Clinical Pathology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Mammary tumors are the most common neoplasm in female dogs and are considered important health problems. In this study we aimed to investigate Transforming Growth Factor Beta-1 (TGF-β1) expression in canine mammary carcinomas (CMCs) by immunohistochemistry and its relationships with histologic grading, survival rate, and recurrence. Tissues were selected from 35 cases of CMCs and were included in a 2-year follow-up study. Immunohistochemistry for detection of TGF-β1 protein was carried out using Avidin-Biotin Complex (ABC) method, and the immunostained slides were scored according to the distribution and intensity of positive reactions. Results indicated that TGF β-1 expression increased significantly in CMCs in comparison to canine normal mammary gland (P < 0.05), 6/35 (17.14%) of tumor samples showed weak immunoreactivity, 15/35 (42.85%) moderate, and 14/35 (40%) showed strong immunoreactivity for TGF-β1. It is also revealed that TGF β-1 increased expression is in significant relationships with higher histologic grades and shorter survival rate after 2 years but not with tumor recurrence.

Barrett-Lee P, Travers M, Luqmani Y (1990) Coombes RC. Transcripts for transforming growth factors in human breast cancer: clinical correlates Br J Cancer 61:612–617PubMed

Benson JR (2004) Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol 5:229–239CrossRefPubMed

Bierie B, Moses HL Transforming growth factor beta (TGF-β) and inflammation in cancer. Cytokine Growth Factor Rev 21:49–59. doi:10.1016/j.cytogfr.2009.11.008

Christeli E, Zoumpourlis V, Kiaris H, Ergazaki M, Vassilaros S, Spandidos D (1996) TGF-beta 1 overexpression in breast cancer. Oncol Rep 3:1115–1118PubMed

Cui W, Fowlis D, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst R (1996) TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86:531–542CrossRefPubMed

Derynck R, Akhurst R, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29:117–129CrossRefPubMed

Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, Berthois Y (2006) Determination of TGFβ1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer 94:239–246. doi:10.1038/sj.bjc.6602920 CrossRefPubMedPubMedCentral

Ghellal A, Li C, Hayes M, Byrne G, Bundred N, Kumar S (2000a) Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. Anticancer Res 20:4413–4418PubMed

Ghellal A, Li C, Hayes M, Byrne G, Bundred N, Kumar S (2000b) Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. Anticancer Res 20:4413–4418PubMed

Gilbertson SR, Kurzman ID, Zachrau RE, Hurvitz AI, Black MM (1983) Canine mammary epithelial neoplasms: biologic implications of morphologic characteristics assessed in 232 dogs. Vet Pathol 20:127–142CrossRefPubMed

Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA (1992) Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res 52:6949–6952PubMed

Heldin C-H, Landström M, Moustakas A (2009) Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial–mesenchymal transition. Curr Opin Cell Biol 21:166–176. doi:10.1016/j.ceb.2009.01.021 CrossRefPubMed

Imamura T, Hikita A, Inoue Y (2012) The roles of TGF-β signaling in carcinogenesis and breast cancer metastasis. Breast Cancer 19:118–124. doi:10.1007/s12282-011-0321-2 CrossRefPubMed

Iyer S, Wang ZG, Akhtari M, Zhao W, Seth P (2005) Targeting TGFbeta signaling for cancer therapy. Cancer Biol Ther 4:261–266CrossRefPubMed

Khanna C, Lindblad-Toh, K., Vail, D., London, C., Bergman, P., Barber, L., Breen, M.,, Kitchell B, McNeil, E., Modiano, J.F., Niemi, S., Comstock, K.E., Ostrander, E.,, Westmoreland S, Withrow, S. (2006) The dog as a cancer model Nat Biotechnol 24:1065–1066.

Klopfleisch R, Lenze D, Hummel M, Gruber A (2010a) Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles. BMC Cancer 10:618CrossRefPubMedPubMedCentral

Klopfleisch R, Schutze M, Gruber AD (2010b) Downregulation of transforming growth factor beta (TGFbeta) and latent TGFbeta binding protein (LTBP)-4 expression in late stage canine mammary tumours. Veterinary journal (London, England : 1997) 186:379–384. doi:10.1016/j.tvjl.2009.09.014 CrossRef

Lebrun J-J (2012) The dual role of TGF in human cancer: from tumor suppression to cancer metastasis ISRN. Mol Biol 2012:28. doi:10.5402/2012/381428

Misdorp W (1999) Histological classification of mammary tumors of the dog and the cat. Armed Forces Institute of Pathology

Misdorp W (2002) Tumors of the mammary gland. In: M DJ (ed) Tumors in domestic animals, 4th edn. Iowa State Press, Ames, IA, pp 575–606 764

Munson L, Moresco A (2007) Comparative pathology of mammary gland cancers in domestic and wild animals. Breast Disease 28:7–21CrossRefPubMed

PANIS C, HERRERA AC, VICTORINO VJ, ARANOME AMF, CECCHINI R (2013) Screening of circulating TGF-β levels and its clinicopathological significance in human breast cancer. Anticancer Res 33:737–742PubMed

Patnaik AK, Hurvitz AI, Lieberman PH (1980) Canine hepatic neoplasms: a Clinicopathologic study. Veterinary Pathology Online 17:553–564. doi:10.1177/030098588001700504 CrossRef

Pena LL, Nieto AI, Perez-Alenza D, Cuesta P, Castano M (1998) Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 10:237–246CrossRef

Rivera P, von Euler H (2011) Molecular biological aspects on canine and human mammary tumors. Veterinary Pathology Online 48:132–146. doi:10.1177/0300985810387939 CrossRef

Roberts AB (1998) Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 24:111–119CrossRefPubMed

Saunier EF, Akhurst RJ (2006) TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 6:565–578CrossRefPubMed

Sottnik JL, Thamm DH Interleukin-11 receptor alpha is expressed on canine osteosarcoma. Vet Comp Oncol 8:96–102

Taylor M, Parvani J, Schiemann W (2010) The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-β in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 15:169–190. doi:10.1007/s10911-010-9181-1 CrossRefPubMedPubMedCentral

Wakefield LM, Piek E, Bottinger EP (2001) TGF-beta signaling in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 6:67–82CrossRefPubMed

Wakefield LM, Yang YA, Dukhanina O (2000) Transforming growth factor-beta and breast cancer: lessons learned from genetically altered mouse models. Breast Cancer Res 2:100–106CrossRefPubMedPubMedCentral

Yoshida K et al (2013) Transforming growth factor-β transiently induces vimentin expression and invasive capacity in a canine mammary gland tumor cell line. Res Vet Sci 94:539–541. doi:10.1016/j.rvsc.2012.10.016 CrossRefPubMed

Zarzynska JM (2014) Two faces of TGF-Beta1 in breast cancer. Mediat Inflamm 2014:16. doi:10.1155/2014/141747 CrossRef

Titel: Immunohistochemical expression of transforming growth factor Beta-1 in canine mammary carcinomas: its relationships with histologic grading, survival rate, and recurrence
verfasst von: Massoud Rezaee
Ahmad Reza Movassaghi
Mohsen Maleki
Publikationsdatum: 21.01.2017
Verlag: Springer London
Erschienen in: Comparative Clinical Pathology / Ausgabe 3/2017
Print ISSN: 1618-5641
Elektronische ISSN: 1618-565X
DOI: https://doi.org/10.1007/s00580-017-2410-x

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Immunohistochemical expression of transforming growth factor Beta-1 in canine mammary carcinomas: its relationships with histologic grading, survival rate, and recurrence

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Haematopoietic induction and hepatic protective roles of Hepacare® in CCl4-induced hepatic damaged rats

Overexpression of the giant FAT1 cadherin gene and its prognostic significance in de novo acute leukaemia patients

Pathological and biochemical studies on enterotoxemia in sheep

The effect of detomidine on clinical signs, serum electrolytes, electrocardiographic indices, and cardiac arrhythmias in Camelus dromedarius

Histopathological study in wild freshwater stingrays Potamotrygon motoro in the Peruvian Amazon

Effect of salbutamol against the experimental acute colitis in rat model

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien